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ress: County Hospital LSummary Adjustable maintenance dosing with either budesonide/formoterol or
budesonide was compared in asthma patients.
This double-blind trial randomized 133 patients (mean forced expiratory volume
in 1 s 66% predicted) to receive 2 inhalations twice daily of budesonide/formoterol
160/4.5 mg (640/18 mg/day) or budesonide 320 mg (1280 mg/day) for 4 weeks. The
study drug was adjusted in both groups according to symptoms to 2–4 inhalations
daily during Weeks 5–8 and 1–4 inhalations daily during Weeks 9–20.
Asthma was well controlled in both groups, with minimal levels of treatment
failure (5 budesonide/formoterol vs. 2 budesonide patients; P ¼ NS) and minimal use
of reliever therapy. Clinically important improvements in health-related quality of
life (HRQL) occurred in the physical functioning and emotional role functioning
domains (both Po0:05) for the budesonide/formoterol group compared with
budesonide. Physician and patient treatment satisfaction favored budesonide/
formoterol (both Po0:05). Budesonide/formoterol patients used fewer daily
inhalations of study drug (P ¼ 0:024). The median average daily inhaled corticoster-
oid dose during the study was 448 mg with budesonide/formoterol and 1152mg with
budesonide.
Adjustable maintenance dosing with budesonide/formoterol and budesonide
resulted in high levels of asthma control. Adjustable budesonide/formoterol
treatment achieved greater HRQL benefits and patient satisfaction, with lower
overall drug use.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The goal of asthma therapy is to achieve early and
optimal control of symptoms and then to maintain
control using the lowest adequate dose of medica-
tion.1 Current international and national asthma
guidelines advocate a stepwise approach to asthma
therapy1–4 and recommend that patients with
persistent asthma receive inhaled corticosteroids
(ICS).
Studies of patients who are not well controlled
on low to moderate doses of ICS have shown that
addition of a long-acting b2-agonist (LABA) to ICS
therapy provides greater clinical benefit, in terms
of improvements in symptoms and lung function,
than increasing the dose of ICS.5–12 It has also been
shown that adding a LABA is at least as effective as
doubling the dose of ICS in preventing severe
exacerbations.8,10,11,13 Indeed, addition of a LABA
to ICS therapy is a recommended strategy for
maintaining control of asthma using a lower overall
steroid load. This concept has become well
established, with patients who use LABA therapy
together with an action plan being able to lower
their overall ICS dose to a greater extent than
patients using ICS therapy alone.1,14 The addition
of a LABA to ICS therapy allows asthma control to
be maintained at a lower overall ICS dose,
but optimal regimens for stepping down have yet
to be determined and stepping down ICS treat-
ment too far with LABA therapy can induce
greater airway inflammation during a period of
exacerbation.15
Tailoring ICS treatment to achieve optimal
asthma control can be achieved by starting with
high doses and then stepping down the dose
according to symptom-based criteria.16,17 Alterna-
tively, patients can be started on low doses of ICS or
ICS/LABA with the ICS dose being stepped up
periodically until asthma is well controlled or a
maximum dose is reached.18 Although this latter
approach may achieve effective control in many
patients, adjustments in the ICS dose can be made
too late to optimize exacerbation control. In
addition, if the ICS dose is not subsequently
reduced from the higher doses when patients’
asthma is stabilized, it is possible that patients
may be overtreated for long periods.
As asthma is characterized by periods of worsen-
ing symptoms and exacerbations, treatment regi-
mens need to be sufficiently versatile to enable
stepping up at the earliest signs of asthma worsen-
ing and stepping down to the lowest effective dose
once control has been achieved.1,2 Patients adopt-
ing adjustable dosing regimens are able to change
their ICS and LABA doses in line with theirsymptoms to maintain optimal control. Asthma
treatment guidelines recognize the advantages of
versatile treatment regimens and stress the need
for self-management action plans, whereby pa-
tients are given written guidance on how to adjust
their reliever medication according to their level of
asthma control.1,2 When used appropriately, self-
management strategies combined with a written
action plan and effective treatment can improve
asthma outcomes.19 Open-label studies using the
ICS/LABA combination budesonide/formoterol
(Symbicorts, AstraZeneca, Lund, Sweden) have
shown that adjustable dosing of both ICS and LABA
components improves asthma control compared
with a higher fixed dose of ICS/LABA.20–23 Adjus-
table dosing with budesonide vs. a higher fixed dose
has also been examined and was shown to be
similarly effective in a double-blind setting.24
Although all of these studies demonstrate the
benefits of adjustable dosing, a comparison of
adjustable dosing with budesonide/formoterol vs.
adjustable dosing with budesonide alone in a
double-blind setting has yet to be performed.
This double-blind study examined the effects of
adjustable maintenance dosing with budesonide/
formoterol (160/4.5 mg) or higher-dose budesonide
(320 mg); the ICS dose per inhalation was 2-fold
higher in patients treated with budesonide than in
those treated with budesonide/formoterol. The ICS
doses were initiated at, and could be adjusted back
up to, a maximum of 640 mg/day in budesonide/
formoterol-treated patients or 1280 mg/day in
those receiving budesonide. Treatment failure,
health-related quality of life (HRQL) and daily
asthma control were assessed over a period of 5
months to determine the relative clinical benefits
of both regimens.Patients and methods
Patients
Patients were recruited into this study (BA-039-
0001) from 16 primary healthcare and hospital sites
across Austria. Men and women (aged X19 years)
with asthma (indicated by a record of reversibility
of forced expiratory volume in 1 s [FEV1] to a short-
acting bronchodilator of X15% or 200ml within 1
month prior to enrollment) and an FEV1 of 40–85%
of predicted normal were included in the study. All
patients had a requirement for ICS or ICS/LABA
combination therapy within the given starting dose
range, as judged by the investigator.
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Figure 1 Design of a 20-week study comparing adjustable maintenance dosing with either budesonide/formoterol 160/
4.5 mg or budesonide 320 mg in patients with asthma.
BUD/FORM vs. higher-dose BUD in asthama 553Patients were excluded from the study if they:
had experienced an asthma exacerbation requiring
oral steroids in the 4 weeks before study entry or an
upper respiratory tract infection in the 6 weeks
before study entry; were current smokers; had
severe cardiovascular disease or other significant
concomitant disease; were receiving another in-
vestigational drug; or if they were pregnant or
planning a pregnancy. Patients receiving treatment
with anti-asthma therapy (other than oral steroids)
were allowed to participate providing that this
treatment was discontinued at study entry. Other
medication that was considered necessary for
patients’ safety and wellbeing was given during
the study at the discretion of the investigator.
Study design
This was a 20-week, randomized, double-blind,
parallel-group study. The study was conducted in
accordance with the Declaration of Helsinki and
approved by the ethics committee at each centre.
Written informed consent was obtained from each
patient. Patients could be withdrawn if they were
nonadherent with study medication or if they
experienced two asthma exacerbations requiring
oral steroids. Eligible patients were initially rando-
mized to treatment with fixed dosing of either
budesonide/formoterol (Symbicorts Turbuhalers)
(160/4.5 mg, 2 inhalations twice daily) or budeso-
nide (Pulmicorts Turbuhalers) (320 mga, 2 inhala-
tions twice daily) according to a computer-
generated randomization schedule. Patients were
randomized to the treatment on Day 0 (baseline)
and returned for further examinations at Weeks 2,
4, 8, 12, 16, and 20 (end of study).
Patients were transferred to an adjustable dosing
regimen from Week 4. At the Week 4 visit—and ataAverage delivered dose, corresponding to a metered dose of
400mg.each monthly visit thereafter—study investigators
assessed patients’ peak expiratory flow (PEF) and
their respiratory symptoms during the past month
and adjusted patients’ doses for the next month
accordingly. Dose adjustments were performed
according to local asthma guidelines and in line
with the recommendations provided by the Aus-
trian Society for Lung Diseases and Tuberculosis.25
At Week 4, patients were transferred to an
adjustable dosing regimen of 2–4 inhalations per
day; from Week 8, the allowed dose range was 1–4
inhalations per day (Fig. 1). Doses were only
stepped down—from 2 inhalations twice daily to 1
inhalation twice daily, or from 1 inhalation twice
daily to 1 inhalation daily—at the investigator’s
discretion. Between the monthly visits, patients
were allowed to step up their dosage themselves if,
on two consecutive days, a short-acting bronchodi-
lator was required for symptom relief on two
occasions during the day or a night-time awakening
due to asthma was experienced. Patients stepped
up their medication from 1 inhalation daily to 1
inhalation twice daily or from 1 inhalation twice
daily to 2 inhalations twice daily.
Terbutaline (Bricanyls Turbuhalers) (0.4mgb)
was used as needed for symptom relief throughout
the study.
Efficacy assessments
The primary efficacy endpoint was the number of
patients per treatment group who experienced X1
treatment failure (defined as a severe exacerbation
requiring one or more of: hospitalization; nebulized
b2-agonists; oral steroids; or withdrawal owing to
lack of efficacy or a life-threatening/fatal condi-
tion). Secondary efficacy endpoints included:
HRQL; treatment satisfaction; dose of study med-bAverage delivered dose, corresponding to a metered dose of
0.5mg.
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required their reliever medication to relieve or
prevent symptoms: FEV1 and PEF.
Patients’ demographics and medical histories
were recorded at the baseline visit. HRQL was
assessed using the Medical Outcomes Study Short-
Form (36-item) Health Survey (SF-36).26,27 Differ-
ences between baseline scores and the values at
Week 20 were calculated. Patient and physician
assessments of satisfaction with treatment was
measured at the end of the study using a visual
analog scale (scale 0–100mm, where 0mm ¼ not
satisfying and 100mm ¼ very satisfying). Patients
used daily diaries—which were assessed by the
investigator at each visit—to record morning and
evening PEF, use of terbutaline for symptom relief
or prevention, night-time awakenings due to
asthma, respiratory symptoms, and use of other
medications to treat deterioration of their asthma.
FEV1 was recorded by the investigator at each visit.Safety assessments
Safety assessments included evaluation of adverse
events, which were recorded throughout the study.
Safety data are reported for all patients who
received at least one dose of study medication
and had at least one post-baseline safety evalua-
tion.Statistical methods
Assuming that the incidence of treatment failure
(primary endpoint) with budesonide is 25%, a
sample size of 80 patients per group was required
to give 80% power to demonstrate superiority of
budesonide/formoterol vs. budesonide, given a
true incidence of failure with budesonide/formo-
terol of 8.5% (5% significance level, two-sided
alternative hypothesis). Intent to treat was the
primary approach for the analyses. The intent to
treat population included all patients who had
received at least one dose of study medication and
had a baseline assessment together with at least
one post-baseline evaluation.
Baseline and demographic characteristics and all
efficacy and safety endpoints were analyzed using
standard descriptive statistical methods. No repla-
cement of missing data was performed. The
proportions of patients with treatment failure were
compared using the Cochran–Mantel–Haenszel test,
stratified by center. Exploratory comparisons of
changes from baseline in SF-36 questionnaire
scores, patient/physician satisfaction ratings,study/reliever medication use, FEV1, and PEF were
compared using the Mann-Whitney U-test.Results
Patients
Patients were enrolled and treated between June
2001 and October 2002. A total of 133 patients
were randomized to receive adjustable dosing with
budesonide/formoterol (n ¼ 65) or budesonide
(n ¼ 68). Seven patients (2 budesonide/formoterol
and 5 budesonide patients) had no efficacy mea-
surement on treatment and were eliminated from
the intent to treat population. The intent to treat
population thus comprised 126 patients, with 63
patients in each treatment group. Twenty-four
patients (9 in the budesonide/formoterol group
and 15 in the budesonide group) withdrew after
Week 2. Of these, 11 were lost to follow-up, 4
withdrew owing to an adverse event (one of which
was a serious adverse event), and 9 patients
withdrew for other reasons. The safety population
comprised all randomized patients.
Owing to difficulties in recruitment, fewer
patients were enrolled than originally planned.
The study was therefore not powered to test the
hypotheses for the primary efficacy endpoint. An
exploratory approach to the statistical analysis was
thus considered for all endpoints.
Demographic and baseline characteristics were
generally well balanced across the treat-
ment groups, the exception being that patients in
the budesonide/formoterol group had a median
asthma duration of 10 years compared with 4.5
years for patients receiving budesonide alone
(Table 1).
Efficacy
Primary efficacy variable
Treatment failures were documented for 5 of 63
(8%) patients who received budesonide/formoterol
(all of whom used nebulized b2-agonists) and 2 of 63
(3%) patients in the budesonide group (both of
whom were treated with oral steroids). Treatment
failure rates were similarly low in both treatment
groups. The rate of treatment failure in the
budesonide group was less than the value of 25%
that had been assumed for calculation of the
sample size. Treatment failures were recorded in
3 patients during the fixed dosing period (2 in the
budesonide/formoterol group and 1 in the budeso-
nide group) and in 4 patients during the period of
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Table 1 Demographic and baseline characteristics of patients receiving adjustable maintenance dosing with
either budesonide/formoterol 160/4.5 mg or budesonide 320 mg (intent to treat population).
Characteristic Budesonide 320 mg (n ¼ 63) Budesonide/formoterol 160/4.5 mg (n ¼ 63)
Male/female, n 37/26 30/33
Age, yrs (range) 45 (20–82) 45 (20–80)
Asthma duration, yrs (range) 4.5 (0–30) 10 (0–35)
Documented smoking habit, n (%) 21 (33) 24 (38)
Previous ICS treatment, n (%) 40 (63) 40 (63)
FEV1, % predicted (range) 65 (39–85) 67 (35–88)
FEV1: forced expiratory volume in 1 s; ICS: inhaled corticosteroid.
All values are presented as absolute numbers and percentages (n (%)) or as mean (range), except asthma duration, which is
shown as median (range).
Table 2 Baseline (Week 0) and treatment (Week 20) values by domain for the Short-Form Health Survey (SF-36)
questionnaire, and patient and physician satisfaction ratings of treatment for patients receiving adjustable
maintenance dosing with either budesonide/formoterol 160/4.5 mg or budesonide 320 mg.
Budesonide 320 mg Budesonide/formoterol 160/4.5 mg
Week 0 Week 20 Week 0 Week 20
SF-36 domain
Physical functioning 80.7 87.2 77.6 85.9
Physical role functioning 75.0 81.3 73.8 88.5
Bodily pain 82.0 88.4 78.8 89.6
General health 64.8 69.3 61.7 68.7
Vitality 56.9 66.4 55.4 63.4
Social functioning 86.2 92.7 87.6 93.7
Emotional role functioning 85.2 83.4 86.0 90.5
Mental health 70.0 78.0 71.3 73.5
Satisfaction with treatment (VAS score)
Patient assessment 75.6 85.4
Physician assessment 71.1 83.6y
P ¼ 0.013 for budesonide/formoterol vs. budesonide.
yP ¼ 0:001 for budesonide/formoterol vs. budesonide. VAS: visual analog scale (0–100 [0 ¼ not satisfying; 100 ¼ very
satisfying]). All values are shown as means.
BUD/FORM vs. higher-dose BUD in asthama 555adjustable maintenance dosing (3 in the budeso-
nide/formoterol group and 1 in the budesonide
group). Only 3 exacerbations (2 in the budesonide/
formoterol group and 1 in the budesonide group)
were documented over the last 12 weeks of the
study.
HRQL and treatment satisfaction
Greater HRQL benefits were evident with budeso-
nide/formoterol compared with budesonide alone,
as shown by improvements in SF-36 questionnaire
domain scores between Weeks 0 and 20 (Table 2).
Significant and clinically relevant differences be-
tween the two treatment groups were apparent in
physical functioning (6.0 units; P ¼ 0:025) andemotional role functioning (12.1 units; P ¼ 0:035)
(Fig. 2). Patients treated with budesonide/formo-
terol showed a trend towards greater improve-
ments for the domains of physical role functioning,
bodily pain, general health, vitality, and social
functioning. Although patients in the budesonide
group showed a greater improvement in mental
health domain scores than those receiving budeso-
nide/formoterol, this difference was not statisti-
cally significant.
Treatment satisfaction with budesonide/formo-
terol was ranked as significantly superior to
budesonide treatment by both patients
(P ¼ 0:013) and physicians (P ¼ 0:001) at the end
of the study (Table 2).
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Figure 2 Change in Short-Form Health Survey (SF-36) scores (difference between scores at the Week 20 [end of study]
visit and baseline) in patients receiving adjustable maintenance dosing with either budesonide/formoterol 160/4.5 mg
or budesonide 320 mg.
W.R. Pohl et al.556Lung function
Mean improvements in FEV1 between baseline and
Week 20 were comparable between the treatment
groups (0.36 and 0.37 l for patients treated with
budesonide/formoterol and budesonide, respec-
tively), as were average morning and evening PEF
values recorded during the study. The mean
morning PEF for patients in the budesonide/
formoterol and budesonide treatment groups was
407 and 398 l/min, respectively; the corresponding
values for mean evening PEF were 411 and 404 l/
min, respectively.
Use of study drug
Patients in the budesonide/formoterol group used
significantly fewer inhalations of study medication
compared with those in the budesonide group (Fig.
3a). The mean number of inhalations per day for
patients receiving budesonide/formoterol vs. bu-
desonide was 3.1 vs. 3.4, respectively (P ¼ 0:024),
corresponding to mean daily ICS doses of 494 and
1072 mg, respectively. Expressed in terms of median
inhalations per day, patients who received budeso-
nide/formoterol used 2.8 inhalations daily (ICS
dose of 448 mg) compared with 3.6 inhalations daily(ICS dose of 1152 mg) for those in the budesonide
group (Fig. 3b), giving a difference of approxi-
mately 700 mg (61%) in the ICS dose.
For patients with diary assessments on at least 5
clinic visits, a total of 36/47 (77%) patients
receiving budesonide/formoterol and 25/42 (60%)
patients receiving budesonide stepped down their
medication during the study. Of the patients who
stepped down, 21/36 (58%) patients in the budeso-
nide/formoterol group and 15/25 (60%) patients in
the budesonide group did not step up their
medication again.
Most patients in both groups reported minimal
requirement for reliever therapy. Seventy-five per
cent of patients in the budesonide/formoterol
group used reliever for symptom relief on less than
1 day per week. Fifty per cent of patients in the
budesonide/formoterol group were reliever-free on
99% of the days in the study compared with 96% of
study days being reliever-free for 50% of the
patients receiving budesonide (Fig. 3c). There was
no difference between the two treatment groups in
the percentage of days on which patients used
reliever medication for symptom relief, although
patients in the budesonide/formoterol group used
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Figure 3 Box and whisker plots for drug use during the treatment period: (a) intake of study medication (number of
inhalations/day); (b) intake of inhaled corticosteroid (mg/day); (c) reliever-free days (percentage of days that no
reliever medication was used for symptom relief or symptom prevention) in patients receiving adjustable maintenance
dosing with either budesonide/formoterol 160/4.5 mg or budesonide 320 mg. Median and mean values are shown.
Outliers lie at least 1.5 box lengths from the end of the box and extreme outliers lie at least 3 box lengths from the end
of the box.28
BUD/FORM vs. higher-dose BUD in asthama 557reliever medication for the prevention of symptoms
on a significantly lower percentage of days (mean
16.2%) than those in the budesonide group (mean
17.4%; P ¼ 0:040).Safety
A total of l55 adverse events were documented (74
in the budesonide/formoterol group and 81 in the
budesonide group). The most frequently reported
adverse events were related to the immune and
respiratory systems. Twenty adverse events were
regarded as being treatment-related: 3 cases each
of myalgia and nervousness, and 1 instance each of
heart disorder, dyspnea, rhinitis, pruritis, and taste
alteration in budesonide/formoterol patients; in
the budesonide group, there were 3 reports of
candidiasis and 2 reports of dysphonia, withcheilitis, stomatitis, asthma, and laryngitis each
being recorded once. There were no reports of
candidiasis or dysphonia in patients treated with
budesonide/formoterol.
There were no treatment-related serious adverse
events. Three patients reported serious adverse
events in connection with hospitalization: an
accident and a planned cardiac examination in
the budesonide/formoterol group and an evalua-
tion of hypertension in the budesonide group.Discussion
In this study—the first double-blind trial to com-
pare adjustable maintenance dosing with an ICS/
LABA with adjustable maintenance dosing using an
ICS alone—we have shown that adjustable main-
ARTICLE IN PRESS
W.R. Pohl et al.558tenance dosing with both budesonide/formoterol
and higher-dose budesonide maintains effective
asthma control. There were few treatment failures
in either group and the majority of patients
required reliever medication on very few days of
the study. Current asthma guidelines advocate
gaining control of asthma, and subsequently main-
taining this, using a stepwise approach to ther-
apy.1–4 Treatment should be tailored to the severity
of the condition and to the individual patient by
using the lowest adequate dose of medication.1
Adjustable maintenance dosing enables patients
with asthma to be treated according to these
guidelines, taking into account the variable nature
of the condition and thereby avoiding patients
being temporarily undertreated at the onset of an
exacerbation or overtreated during periods when
asthma is quiescent.
In this study, patients receiving adjustable main-
tenance dosing with budesonide/formoterol used
reliever medication for symptom relief on a median
of 0.72% of the study days (i.e. 50% of patients used
reliever medication on only 1 day during the 5-
month study). This result compares favorably with
the data obtained for patients in the budesonide
treatment group, where median use of reliever
medication for symptom relief was around 6 days.
In this study, the low levels of reliever medication
use and exacerbations illustrate the high degree of
asthma control that was achieved in most patients
with the adjustable maintenance dosing regimens.
The very low levels of as-needed medication used
in most patients throughout the study allowed us to
confidently conclude that most patients had well-
controlled asthma during this 5-month assessment
period. Failure to achieve guideline-defined levels
of control—i.e. freedom from exacerbations, no
nocturnal awakenings, minimal daily symptoms and
reliever medication use—can often be explained by
a single outcome measure, and this measure can be
the requirement for excess reliever medication.29
Indeed, this study suggests that stepping down
treatment using an adjustable maintenance dosing
regimen with ICS/LABA or ICS alone can achieve
and maintain well-controlled asthma in many
patients, including guideline-defined control as
reported in a recent study by Bateman and co-
workers.18
Several studies have shown that patients with
asthma treated with ICS alone can have their ICS
dose reduced without compromising asthma con-
trol.16,17 Rapid and optimal asthma control is
achievable in most patients with poorly controlled
asthma treated initially with high doses of budeso-
nide (1600 or 3200 mg per day).16 In patients
stabilized on high-dose ICS therapy, doses can bereduced according to symptom-based criteria with-
out compromising disease control.16,17 Asthma
control, as reflected in bronchial hyperreactivity
and composite symptom control, can still continue
to improve on a weekly basis while ICS therapy is
being reduced.16,30 Foresi and colleagues24 re-
ported that in patients with moderate asthma
who achieved a stable clinical condition with
budesonide 1600 mg per day, budesonide 200 mg
per day subsequently maintained control as effec-
tively as a 4-fold higher dose (budesonide 800 mg
per day) when patients were able to adjust their
treatment in response to signs of deteriorating
asthma control, such as a fall in PEF. We have shown
that, in addition to maintaining asthma control at a
lower overall ICS dose, adjustable maintenance
dosing with ICS/LABA results in better HRQL
benefits and improved patient satisfaction com-
pared with an adjustable dosing regimen with ICS
alone.
Downward dose adjustments have been shown to
be facilitated with ICS plus LABA treatment
compared with treatment involving ICS alone. In a
6-month, placebo-controlled study, Wilding and
associates14 assessed the effect of adding salme-
terol to the treatment regimen of patients who
adjusted their ICS dose in accordance with guide-
lines. Addition of salmeterol reduced the ICS dose
by 17%, with no change in exacerbations or use of
oral steroids. In the present study, the starting dose
of ICS was 50% lower in the budesonide/formoterol
group than in the budesonide group. Over the
whole trial period, the median ICS dose was 61%
lower with budesonide/formoterol and effective
control of asthma was maintained. Use of an
adjustable maintenance regimen may therefore
avoid the need for excessive doses of ICS, which
may be associated with the risk of systemic adverse
events.31
It is now firmly established that the combination
of an ICS and a LABA delivers better daily symptom
control than double the dose of ICS, with compar-
able exacerbation control.13 However, if the dif-
ference in ICS dose between the treatment groups
in a study is too great, more exacerbations are
encountered in patients treated with the lower ICS
dose, irrespective of whether LABA is coadminis-
tered7 or not.24 Similarly, if the steroid dose is
reduced too far under the cover of as-needed
salmeterol treatment, more inflammation is en-
countered when patients have exacerbations.15
This potential problem was not apparent in the
current study, as the ICS dose was never allowed
to drop too low in the adjustable dosing group
nor to remain low if a loss in control was
encountered.
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BUD/FORM vs. higher-dose BUD in asthama 559Patients in the budesonide/formoterol group had
greater HRQL benefits compared with those treated
with budesonide alone. Clinically relevant differ-
ences between the two groups were apparent for
the SF-36 domains of physical functioning and
emotional role functioning. A previous study com-
paring treatment with budesonide and formoterol
with therapy with budesonide alone or with
nonsteroidal anti-asthma therapy found that
both budesonide and budesonide plus formoterol
improved HRQL compared with nonsteroidal
anti-asthma therapy (assessed using the SF-36
questionnaire and the Asthma Quality of Life
Questionnaire).32 However, no differences in HRQL
were detected between fixed-dose budesonide and
budesonide plus formoterol. This is, therefore, to
our knowledge the first study to demonstrate a
clinically relevant improvement in HRQL domains
using the SF-36 for patients when treated with
ICS/LABA compared with ICS alone. While the SF-36
is a widely used generic health status question-
naire, and is often used in conjunction with a
disease-specific questionnaire in clinical studies, its
use in asthma research has also been validated.33
Generic questionnaires are more likely to detect
the effects of comorbidities, but since the present
study was randomized, the differences we observed
in SF-36 scores are likely to have been a result of
asthma or its treatment.
Although similar exacerbation control was seen
in the budesonide/formoterol and budesonide
groups in the current study, it should be noted that
the exacerbation rate in this 5-month study was far
lower than expected. Consequently, studies of a
longer duration are warranted to determine
whether adjustable maintenance dosing with bu-
desonide/formoterol or a higher dose of budeso-
nide alone maintains exacerbation control in
patients with more severe asthma. A larger sample
size would enable this hypothesis to be tested with
a reduced possibility of a type I error for the
primary efficacy endpoint. Nevertheless, this trial
confirmed the good levels of control seen with
adjustable-dose budesonide/formoterol in several
other recent studies.20–23,33–36 All of these studies
showed that budesonide/formoterol could maintain
or improve asthma control at a reduced drug load
compared with fixed-dose budesonide/formoterol.
The present study extends the knowledge of
budesonide/formoterol adjustable dosing by com-
paring its effect vs. a 2-fold higher dose of
budesonide.
In conclusion, this double-blind study suggests
that adjustable maintenance dosing with budeso-
nide/formoterol maintains asthma control as effec-
tively as adjustable maintenance dosing withbudesonide alone, whilst providing better HRQL
benefits and greater treatment satisfaction. The
benefits observed in the budesonide/formoterol
group were achieved with a 61% lower median daily
ICS dose and minimal use of reliever medication,
demonstrating that adjustable maintenance dosing
with budesonide/formoterol is in line with asthma
treatment guidelines, providing asthma control at
the lowest effective dose.Acknowledgements
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